|
|
Volumn 8, Issue 11, 2009, Pages 833-834
|
|
Novel pharmacotherapies for obesity poised to enter market
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMFEBUTAMONE;
AMFEBUTAMONE PLUS NALTREXONE;
AMFEBUTAMONE PLUS ZONISAMIDE;
CONTRAVE;
EMPATIC;
FENFLURAMINE;
LORCASERIN;
NALTREXONE;
PHENTERMINE;
PHENTERMINE PLUS TOPIRAMATE;
PLACEBO;
QNEXA;
RIMONABANT;
SIBUTRAMINE;
TARANABANT;
TOPIRAMATE;
UNCLASSIFIED DRUG;
ALCOHOLISM;
ANXIETY DISORDER;
ARTICLE;
BARIATRIC SURGERY;
CLINICAL TRIAL;
COGNITIVE DEFECT;
COMBINATION CHEMOTHERAPY;
CONFUSION;
DEPRESSION;
DIET THERAPY;
DRUG ACTIVITY;
DRUG DESIGN;
DRUG EFFICACY;
DRUG SAFETY;
EXERCISE;
HEART DISEASE;
HOMEOSTASIS;
HUMAN;
LOW DRUG DOSE;
MEMORY DISORDER;
MONOTHERAPY;
OBESITY;
OPIATE ADDICTION;
PRIORITY JOURNAL;
SUICIDAL IDEATION;
SUICIDE;
ADULT;
ANTI-OBESITY AGENTS;
APPETITE;
CLINICAL TRIALS, PHASE III AS TOPIC;
HUMANS;
OBESITY;
SATIETY RESPONSE;
UNITED STATES;
|
|
EID: 70350749743
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3044 Document Type: Article |
|
Times cited : (14)
|
|
References (0)
|